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ORIGINAL STUDIES

Mechanical circulatory support in acute myocardial infarction
and cardiogenic shock: Challenges and importance of
randomized control trials
Mir B. Basir DO1

|

Duane S. Pinto MD2
1

Akshay Khandelwal MD
Andrew Althouse PhD4

| Boback Ziaeian MD, PhD3

| Jennifer Cowger MD

1

|

3

William Suh MD

|

|

1

Cardiology, Henry Ford Health System,
Detroit, Michigan

Abstract

2

Background: Acute myocardial infarction (AMI) complicated by cardiogenic shock

Cardiology, Beth Israel Deaconess Medical
Center, Boston, Massachusetts
3

Cardiology, Riverside Medical Clinic,
Chattaroy, Washington
4
Medicine, University of Pittsburgh,
Pittsburgh, Pennsylvania

Correspondence
Mir B. Basir, DO, FSCAI, FACC, Director,
Acute Mechanical Circulatory Support,
Director, STEMI, Henry Ford Hospital, 2799
W. Grand Blvd, K-2 Cardiac Catheterization
Laboratory, Detroit, MI 48202.
Email: mbasir1@hfhs.org

(CS) is associated with significant morbidity and mortality.
Methods: We provide an overview of previously conducted studies on the use of
mechanical circulatory support (MCS) devices in the treatment of AMI-CS and difficulties which may be encountered in conducting such trials in the United States.
Results: Well powered randomized control trials are difficult to conduct in a critically
ill patient population due to physician preferences, perceived lack of equipoise and
challenges obtaining informed consent.
Conclusions: With growth in utilization of MCS devices in patients with AMI-CS,
efforts to perform well-powered, randomized control trials must be undertaken.
KEYWORDS

acute myocardial infarction/STEMI, cardiogenic shock, clinical trials, ECMO/IABP/Tandem/
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device is intra-aortic balloon pump counter-pulsation (IABP).
Despite several observational studies suggesting the benefit of

Cardiogenic shock (CS) is a frequent and deadly complication of acute

IABP, RCTs have failed to demonstrate significant mortality benefit

myocardial infarction (AMI).1-3 With advancements in medical ther-

when compared to medical therapy.7-9 Veno-arterial extracorporeal

apy, early revascularization and regional systems of care, the risk of

membrane oxygenation (ECMO) has been available for many

death from AMI without CS is 2%.4 However, in the 4–8% of

decades, however, widespread adoption has been limited given the

patients who develop CS, the risk of in-hospital death is higher,

high level of expertise needed, typically requiring dedicated perfu-

33–50%.1-4 With the seminal publication of the “Shock Trial,” early

sionists. ECMO is utilized at select centers despite little evidence

revascularization demonstrated improved survival in patients with

of improved outcomes. Meta-analyses of observational studies

AMI and cardiogenic shock (AMICS) in a randomized control trial

demonstrate survival to discharge rates below 50% as well as fre-

5

(RCT). Despite two decades of medical advancements little gains

quent complications including high rates of stroke and vascular

have been made in improving the morbidity and mortality associated

access complications.13-19 Technological advancements over the

6-10

with AMICS.

past decade have led to the development of several commercially

Mechanical circulatory support (MCS) devices improve hemo-

available percutaneous, temporary, MCS devices to serve as

dynamics in patients with AMICS and use of such devices as

adjunctive therapies to revascularization. Current MCS technolo-

adjunctive therapy is supported in US guidelines (Class II a/b rec-

gies include Impella (Abiomed, Danvers, MA), Tandem Heart

ommendations).11,12 The most widely available and utilized MCS

(LivaNova, London, UK), Heartmate PHP (Abbott, Abbott Park, IL),
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and smaller, mobile, ECMO circuits such as CardioHelp (Maquet,

use of invasive hemodynamics to guide therapies including escalation

Wayne, NJ). These devices differ in their methods of use, ease of

and weaning of inotropes and MCS.21 Survival in patients improved

placement, cannula size, flow capacity, effect on intra-cardiac

from historic rates of 50% to >70%.22 The study was extended

hemodynamics and complication rates (Table 1).

nationally and findings of improved survival against historical controls

Until recently, these large bore devices had been used sporadi-

were replicated.23 The study, however, has significant limitations.

cally in states of refractory CS, in a relatively small subset of patients.

There was no control arm and results were compared only to histori-

Refractory CS management was largely driven by surgeons utilizing

cal controls. There were a multitude of therapeutic changes that

ECMO. Technological development and increasing familiarity with

occurred simultaneously, and it is unclear how much effect any indi-

MCS led to a migration of shock management from the operating

vidual therapy made, including use of MCS. Salvage patients

room into the catheterization laboratory and shock teams have

(unwitnessed OHCA, cardiac arrest >30 min, patients with signs of

expanded to include interventional and advanced heart failure special-

anoxic brain injury) were excluded from the protocol to limit utiliza-

ists. This new CS treatment paradigm led to significant increases in

tion of MCS in patients who may not gain significant benefit. Other

the use of MCS with a diffusion of MCS utilization to centers without

centers, including Inova Heart and Vascular Institute and the Univer-

LVAD/Transplant programs.2,3,20 Variability in MCS utilization and

sity of Utah, in observational studies, have similarly shown improved

outcomes fostered the development of multidisciplinary, intra- and

outcomes through formalized shock teams and protocols.24-25

inter-facility CS teams with the aims of rapid recognition and manage-

MCS is an expensive medical intervention with inherit industry,

ment of CS. This strategy has been comprehensively implemented in

physician and health system financial interests that incentivize utiliza-

Detroit where investigators across five large health care systems cre-

tion. Given the cost of MCS and associated care, and as we transition

ated a shock protocol to share among physicians in their centers. The

to value-based care, concerns about the demonstrated clinical bene-

protocol was based on observed “best practices” and implemented in

fits have also been magnified. MCS devices require large bore access

an effort to improve local outcomes and unify significant variability

and anticoagulation with the risk of fatal vascular complications,

among physicians and health care systems. The implementation of the

which may be under reported in observational studies, potentially mit-

shock protocol resulted in a multifactorial change from recognition to

igating clinical benefits. The few RCT of MCS conducted to date have

treatment. The protocol emphasized the need for (1) early recognition

not

and catheterization laboratory activation for patients who present in

readdressed by Amin et al. after they reported increasing in-hospital

AMICS, (2) early use of MCS prior to a state of refractory CS and (3)

mortality, bleeding requiring transfusion, acute kidney injury (AKI),

TABLE 1
Device

demonstrated

improved

survival.

These

concerns

were

Temporary mechanical circulatory support devices and effect
Pump
inflow

Pump
outflow

Device options

Oxygenation

Aortic
flow

RV
support

LV
support

LV
load

RV
load

Right sided support
VV ECMO

Ra,IVC,
svc

Ra,IVC,svc

Centrimag, CardioHelp,
TandemHeart

Y

N/A

N

N

$

$

Centrifugal
RVAD

RA

PA

Centrimag, CardioHelp,
TandemHeart

Y

N/A

Y

N

$

#

Axial
RVAD

IVC

PA

Impella RP

N

N/A

Y

N

$

#

Left sided support
Centrifugal
LVAD

LA

IF

Centrimag, CardioHelp,
TandemHeart

Y

Retrograde

N

Y

#

"

Axial
LVAD

LV

AO

Impella 2.5, Impella CP, Impella
5.0/5.5, PHP

N

Antegrade

N

Y

#

"

Combination support
VA ECMO

RA

IF

Centrimag, CardioHelp, or
TandemHeart

Y

Retrograde

Y

Y

"

#

VAV
ECMO

RA, IVC,
SCV

IVC/SFC
& IF

Centrimag, CardioHelp, or
TandemHeart

Y

Retrograde

Y

Y

"

#$

Note: A combination of isolated right sided support and left sided support can be combined to provide biventricular support (BiPella, EcPella, Bi-Tandem,
etc.). Similarly, ECMO cannulas can be configured in numerous configurations to provide biventricular support and can be cannulated percutaneous or
centrally.
Abbreviations: AO, aorta; ECMO, extracorporeal membrane oxygenation; IF, iliofemoral artery; IVC, inferior vena cava; LA, left atrium; LV, left ventricle;
LVAD, percutaneous left ventricular assist device; PA, pulmonary artery; RA, right atrium; RV, right ventricle; RVAD, right ventricular assist device; SVC,
superior vena cava.
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stroke, length of stay (LOS), and hospital costs with use of Impella

0.24–0.36, p = .02; p = .004 for intergroup comparison]). However,

when compared to IABP.26 It is important to note the significant limi-

complications like severe bleeding (n = 19 vs. n = 8, p = .002) and limb

tations of this analysis, which consists of retrospective, claims-based

ischemia (n = 7 vs. n = 0, p = .009) were encountered more frequently

data, using ICD codes (Premier Healthcare Database).

after Tandem Heart support. Overall, 30-day mortality was similar

In this article the authors review previously conducted studies
and present the difficulties in conducting randomized clinical trials in
AMICS in the United States.

between the two groups (IABP 45% vs. Tandem Heart 43%, logrank, p = .86).
The ISAR-SHOCK trial was a feasibility trial presented in 2008,
randomizing 26 patients with AMICS who received either an IABP or
Impella.28 Compared to patients on IABP support, Impella patients

2
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PRIOR TRIALS

had higher cardiac indices and diastolic arterial pressures after 30 min
of support, however, mortality was 46% (i.e., 6 of 13 patients) in both

Over a decade of results from various trials utilizing MCS strategies

groups after 30 days. The cohort had several high-risk characteristics

for CS management have shown an absence of mortality benefit

including mechanical ventilation on admission in 92% and CPR/VT

(Figure 1). Each trial, however, has been challenged by significant

before randomization in 69–85%. The trial was not designed nor

logistical and ethical barriers impacting patient recruitment, as well as

powered to examine mortality.

the presence of a heterogeneous shock phenotype. While clinical tri-

The Recover II Trial was a multicenter RCT comparing IABP and

als often include hemodynamic and clinical criteria for defining CS, CS

Impella 2.5 in AMICS designed with the primary intent of assessing a

presents on a wide continuum and patient phenotypes can vary based

composite endpoint of major adverse events within 30 days or at hos-

on underlying cardiac etiology and presence or absence of preexisting

pital discharge. The sample size needed to determine significant dif-

systolic dysfunction. The severity of CS, duration of CS, presence of

ferences between groups was 384. Despite 58 sites with IRB approval

isolated versus biventricular cardiac failure, associated comorbidities

in the United States, only one patient enrolled in the study between

and age of patients all impact CS survival. In review of the clinical tri-

July 2008 and August 2010, resulting in discontinuation of the trial.

als below, we will highlight key trial characteristics (Table 2).

The Impella versus IABP Reduces Infarct Size in STEMI

In 2005 Thiele et al.27 conducted a single center RCT comparing

(IMPRESS) trial was a randomized, prospective, open-label, multicen-

IABP to Tandem Heart in 41 patients from 2000–2003.28 The primary

ter trial, with the aim to randomize 130 patients with acute anterior

outcome of this pilot trial was measured cardiac power index (CPI).

STEMI and clinical signs of “pre-cardiogenic” shock, defined as a heart

CPI along with other hemodynamic and metabolic variables were

rate > 100, systolic blood pressure (SBP) <100 mmHg and clinical

improved with Tandem Heart support (from 0.22 [interquartile range

signs of CS including cold extremities, cyanosis, and altered menta-

(IQR) 0.19–0.30] to 0.37 W/m2 [IQR 0.30–0.47, p < .001] when com-

tion.29 Between 2008 and 2011, only 21 patients (n = 12 with Impella)

pared with IABP from 0.22 [IQR 0.18–0.30] to 0.28 W/m2 [IQR

were enrolled and investigators cited the inclusion criteria as the

F I G U R E 1 Timeline of randomized control trials performed to date and currently enrolling, evaluating the efficacy of mechanical circulatory
support in acute myocardial infarction and cardiogenic shock. CS, cardiogenic shock; ECMO, extracorporeal membrane oxygenation; IABP, intraaortic balloon pump counter-pulsation

- Improved cardiac index and diastolic pressures
with use of Impella
- No significant difference in 30 days mortality

- 11 sites active for recruitment
- 50 had IRB approval
- Only one patient was enrolled in 2 years

In 2007 due to slow recruitment the MCS
device to be implanted was changed from
ECMO to Impella but continued with low
recruitment and was terminated
- No significant difference in 30-day mortality
- Initial attempt to enroll pre-shock was
abandoned due to difficultly in identifying the
pre-shock state
- Protocol changed to “severe CS” but
discontinued early due to slow recruitment

- Age < 18 years
- Resuscitation (>30 min)
- HOCM
- Definite LV thrombus
- Severe valvular disease or mechanical valve
- CS caused by mechanical complications
- Predominant RV failure or the need for RV
MCS
- Sepsis
- Known cerebral disease
- Bleeding with a need for surgical intervention
- Pulmonary embolism
- Allergy to heparin or any known coagulopathy
- Significant AI
- Pregnancy
- Inclusion in another study or trial
- Unwitnessed cardiac arrest
- Abnormalities of the aorta
- Recent stroke or TIA
- LV thrombus

- Patient with refractory cardiogenic shock
- Reperfusion > 24 hr after the pain begins

-Severe aorto-iliac disease impeding placement
of either IABP or pMCS
-Known severe cardiac aortic valvular disease
- Known concomitant disease with a life
expectancy of < 1 year
- Participation any other trial within the
previous 30 days
- CABG within the preceding week

- AMI <48 hr
- SBP <90 mmHg and HR >90 bpm or inotropic
drugs to maintain SBP >90 mmHg
- End-organ hypoperfusion (cool extremities or a
urine output of <30 ml/hr) or pulmonary edema
- CI < 2.2 L/min/m2
- PCWP >15 mmHg OR angiographic LVEF <30%
and LVEDP >20 mmHg
- Shock onset < 24 hr

- STEMI undergoing primary PCI
- Patient presents with at least one of the
following:
- Unstable blood pressure
- Tachycardia and tissue hypoperfusion
- The need for inotropic support
- Acute myocardial infarction complicated with
cardiogenic shock
- Patient without contraindication to IABP or
ECLS-Impella
- STEMI
- plan for immediate PCI
-SBP <90 mmHg for >30 min or the need for
inotropes to SBP >90 mmHg.
- Must be mechanically
Ventilated before randomization

Multicentered
RCT
IABP vs. Impella 2.5
26 patients

Multicentered
RCT
IABP vs. Impella 2.5
One patient

RCT
ECLS (addended to Impella)
vs. standard of care

RCT
IABP vs. Impella CP
48 patients

ISARSHOCK
trial
2008

Recover II
trial
2008–10

Massetti
et al.
2009

IMPRESS
trial
2016

- Improved cardiac power index with the use of
tandem heart (primary end point)
- Worse bleeding and limb ischemia with the
use of tandem heart
- No significant difference in 30 day mortality

- Age > 75 years,
- Mechanical complications of AMI
- RV failure
- Sepsis
- Significant AI
- Severe cerebral damage
- Resuscitation >30 min
- severe PAD
- Other diseases with reduced life expectancy

- AMI w/planned PCI (CABG acceptable)
- SBP <90 mmHg or vasopressors to maintain SBP
>90 mmHg
- End-organ failure (e.g., urine output <30 ml/h,
cold skin and extremities, and serum lactate
>2 mmol/L)
- PCWP >15 mmHg
- CI <2.1 L/min/m2
- Shock onset <12 hr

Single center
RCT
IABP vs. tandem heart
41 patients

Thiele et al
2005

Outcome(s)/limitation(s)

Exclusion criteria

Inclusion criteria

Design/sample size

Key trial characteristics from RCTs evaluating MCS in AMICS

Trial

TABLE 2
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(Continues)

Primary outcomes is all cause death at 30-day

- Resuscitation >45 min
- Mechanical cause of cardiogenic shock
- Onset of shock >12 hr
- Severe peripheral artery disease with
impossibility to insert ECLS cannulas
- Age < 18 years or age > 75 years
- Shock of other cause (bradycardia, sepsis,
hypovolemia, etc.)
- Other severe concomitant disease with
limited life expectancy <6 months
- Pregnancy
- Participation in another trial

- Cardiogenic shock complicating AMI (STEMI or
NSTEMI) plus obligatory:
- Planned revascularization (PCI or alternatively
CABG)
- Systolic blood pressure < 90 mmHg >30 min or
catecholamines required to maintain
pressure > 90 mmHg during systole
- Signs of impaired organ perfusion with at least
one of the following criteria (a) altered mental
status, (b) cold, clammy skin and extremities, (c)
oliguria with urine output <30 ml/hr
- Arterial lactate >3 mmoL/L
- Informed consent

Multicenter
RCT
ECMO vs. standard of care
420 patients

ECLSSHOCK
Recruiting

Primary outcomes is death, resuscitated
circulatory arrest and implantation of another
mechanical circulatory support device at
30 days

- Age < 18 years
- Life expectancy lower than 1 year
- High suspicion of pulmonary emboli or cardiac
tamponade as a cause of shock
- Significant bradycardia or tachycardia which
might be responsible for hemodynamic
instability and not treated by pacing or
cardioversion
- Cardiac arrest survivors remaining comatose
- HOCM
- PAD disabling insertion of outflow cannula to
femoral artery
- Moderate to severe aortic regurgitation
- Aortic dissection
- Uncontrolled bleeding or TIMI major bleeding
within last 6 months
- Known encephalopathy

Patients must fulfill criteria either:
A. Rapidly deteriorating CS defined as
hemodynamic instability necessitating repeated
bolus administration of vasopressors to maintain
MAP >50 mmHg + impaired LVEF <35% or LVEF
35–55% in case of severe MR or AS
B. Severe CS defined as:
- Hemodynamic; CI < 2.2 L/min/
m2 + norepinephrine dose >0.1 μg/kg/min
+ dobutamine dose >5 μg/kg/min or
SBP < 100 mmHg + norepinephrine dose
>0.2 μg/kg/min + dobutamine dose >5 μg/kg/
min + (LVEF <35% or LVEF 35–55% + severe
MS or AS)
-Metabolic; lactate - two consecutive values
≥3 mmol/L (>30 min between samples), with
nondecreasing trend on steady doses of
inotropes and/or vasopressors or SvO2 - two
consecutive values <50% (>30 min between
measurements), with nonincreasing trend on
steady doses of inotropes and/or vasopressors
- Hypovolemia must be excluded:
Central venous pressure > 7 mmHg or pulmonary
capillary wedge pressure > 12 mmHg

Multi-center
RCT
ECMO vs. standard of care
120 patients

ECMO-CS
recruiting

Outcome(s)/limitation(s)

Exclusion criteria

Inclusion criteria

Design/sample size

(Continued)

Trial

TABLE 2
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Multi-center
RCT
ECMO vs. standard of care
428 patients

Multi-center
RCT
Impella CP vs. standard of
care
360 patients

Euro shock
Recruiting

DANGER
Recruiting

- STEMI <36 hr duration
Cardiogenic shock <24 hr duration, confirmed by:
- Peripheral hypoperfusion (arterial blood lactate
≥2.5 mmoL/L and/or SvO2 < 55% with a normal
PaO2)
- SBP < 100 mmHg and/or need for vasopressor
therapy
- LVEF <45% or by wall motion score index >1.6

- Other causes of shock (hypovolemia,
hemorrhage, sepsis, pulmonary embolism or
anaphylaxis)
- Shock due to mechanical complication to
myocardial infarction
- Severe AI/AS
- Predominant RV failure
- OHCA with persistent Glasgow coma scale <8
after ROSC
- Shock duration>24 hr
- Known heparin intolerance
- Already established mechanical circulatory
support
- Do not resuscitate wish

Primary outcomes is all-cause death at
6 months

Primary end point is 30 day all cause mortality
Secondary endpoints:
- 12-month all-cause mortality or admission for
heart failure
- 12-month all-cause mortality
- 12 month admission for heart failure
Performance of cost effectiveness analyses and
quality of life measures

- Echocardiographic evidence) of mechanical
cause for CGS: Eg ventricular septal defect,
LV-free wall rupture, ischaemic mitral
regurgitation (recorded within 30 min of end
of PCI procedure)
- Deemed appropriately frail (≥5 Canadian
frailty score)
- Shock from another cause (sepsis,
hemorrhagic/hypovolaemic shock,
anaphylaxis, myocarditis etc.)
- Significant systemic illness
- Known dementia of any severity
- Comorbidity with life expectancy <12 months
- Severe peripheral vascular disease (precluding
access making ECMO contra-indicated)
- Severe allergy or intolerance to
pharmacological or antithrombotic antiplatelet agents
- Out-of-hospital cardiac arrest (OHCA) under
any of the following circumstances:-

- Cardiogenic shock complicating AMI
- Treated with primary PCI
- Presentation CGS within 24 hr of onset of acute
coronary syndrome (ACS) symptoms
- CGS can only be secondary to ACS (type 1 MI
STEMI or N-STEMI) or secondary to ACS
following previous recent PCI (acute/sub-acute
stent thrombosis ARC)
- PCI has been attempted
- Persistence of CGS 30 min after successful or
unsuccessful revascularization of culprit coronary
artery to allow for echocardiography and clinical
assessment
CGS will be defined by the following two criteria:
• Systolic blood pressure < 90 mmHg for at least
30 min, or a requirement for a continuous
infusion of vasopressor or inotropic therapy to
maintain systolic blood pressure > 90 mmHg
Clinical signs of pulmonary congestion, plus signs
of impaired organ perfusion with at least one of
the following manifestations:
Altered mental status
Cold and clammy skin and limbs
Oliguria with a urine output of less than 30 ml per
hour
Elevated arterial lactate level of >2.0 mmol per liter
Provision of informed assent followed by patient
consent; (or relative or physician consent if the
patient is unable to consent)
• Without return of spontaneous circulation
(ongoing resuscitation effort)
• Without pH or > 7 without bystander CPR
within 10 min of collapse- Involved in
another randomized research trial within the
last 12 months
- Arterial lactate level of <2.0 mmol per liter

Outcome(s)/limitation(s)

Exclusion criteria

Inclusion criteria

Abbreviations: AMI, Acute myocardial infarction; CS, cardiogenic shock; ECLS, extracorporeal life support; IABP, intra-aortic balloon pump counter-pulsation; LV, left ventricle; MCS, mechanical circulatory
support; RCT, randomized control trial; RV, right ventricle; SBP, systolic blood pressure.

Design/sample size

(Continued)

Trial

TABLE 2
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primary obstacle; “Although heart rate and blood pressure are objec-

end of 2019. Lastly, planning has begun for the RECOVER IV trial,

tive and easily available measures, it is less easy to define the clinical

which will evaluate outcomes of Impella using best practices incorpo-

pre-shock condition within the continuum from pre-shock to severe

rated from the National Cardiogenic Shock Initiative (NCSI) versus

shock.” The trial enrollment criteria were then revised to include

standard of care. The trial is expected to include an international

patients with “severe shock,” defined as a SBP <90 mmHg or need for

cohort of patients, including those from the United States with plans

inotrope support and the need for mechanical ventilation.30 Using the

to start recruitment in 2021 or 2022.

broader definition, a critically ill cohort was recruited: all patients were
on inotropes and 92% had a cardiac arrest (75% required hypothermia
and 48% achieving ROSC after more than 20 min of CPR). In total,

4
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48 patients with AMICS were recruited and 24 received an Impella CP
and 24 an IABP. At 30 days, mortality in patients treated with either

The current “absence of evidence” of survival benefit with MCS is not

IABP or Impella CP was similar (50 and 46%, respectively, hazard ratio

“evidence of absence” of benefit. The aforementioned trials lack the

[HR] with Impella CP, 0.96 (95% confidence interval [CI] 0.42 to

appropriate sample size to determine if a survival benefit exists or not.

2.18)). At 6 months, mortality for both the Impella CP and IABP was

Possible explanations for low enrollment include physician prefer-

50% (HR 1.04 (95% CI; 0.47–2.32). The main cause of death was neu-

ences, perceived lack of equipoise and challenges in obtaining

rologic injury and refractory CS.

informed consent.

ECMO has not been studied in any RCT in CS. In 2006 Massetti
et al attempted the “Comparison of Standard Treatment Versus Standard Treatment Plus Extracorporeal Life Support (ECLS) in Myocardial

4.1

|

Low incidence

Infarction Complicated with CS trial” which was halted in 2009 due to
slow recruitment.31

The principal challenge in conducting RCT in AMICS is recruitment.
The incidence of AMICS and use of MCS is relatively low.36 The
expertise needed in implanting and more importantly managing MCS

3
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ONGOING TRIALS

devices such as Impella, Tandem Heart, and ECMO is challenging and
currently only a small number of regional centers can perform and

On the horizon RCTs have begun in Europe to help better evaluate

manage these devices safely.37 This challenge was present in the

the utility of MCS in AMICS. ECMO-CS is a multicenter RCT compar-

IMPRESS trial, which mandated that each center have pre-trial experi-

ing current standard of care to ECMO in AMICS.32 The primary end-

ence with at least 10 high-risk PCI procedures with Impella to demon-

point is a composite of death from any cause, resuscitated circulatory

strate the ability to implant and manage this device safely. Even

arrest, and implantation of another MCS device at 30 days. The sam-

among centers with an expertise in the utilization of one form of

ple size of 120 individuals (60 in each arm) provides 80% power to

MCS, one cannot have an expectation that such expertise will trans-

detect a 50% reduction of primary endpoint, at alpha = 0.05. Patient

late into the management of other forms of MCS and therefore cen-

recruitment started in October 2014. Similarly, Thiele et al have begun

ters with a high expertise in multiple MCS modalities are further

the “ECLS-Shock” trial comparing ECMO with standard of care in a

limited.37 Though the use of these devices is expanding to community

33

420 patient multicenter study, evaluating 30-day mortality.

The trial

programs, these initiatives are usually led by a physician leader and at

will only enroll patients with a lactate >3 mmoL/L, exclude patient

times do not cultivate in other operators or the institution as a whole.

with resuscitation >45 min or those with shock onset >12 hr. The
study will use a large working group of hospitals with the goal of completing recruitment within 3 years. Banning et al. have begun the Euro

4.2

|

Heterogeneous patient phenotype

Shock trial, the largest trial planned to date evaluating the use of
ECMO versus standard of care; with a goal recruitment of 428 patients

CS in clinical trials is often defined using both hemodynamic and clini-

across 44 European centers.34

cal signs and/or symptoms. Definitions used in trials vary and include

The Danish CS (DanShock) trial is a multicenter, RCT, comparing

evidence of persistent hypotension (SBP < 80–90 mmHg or a mean

Impella CP with standard of care that is currently enrolling in Den-

arterial pressure 30 mmHg below baseline) with a low-cardiac index

mark.35 Due to slow recruitment, sites in Germany have been added

(<1.8 L/min/m2 without support or < 2.0–2.2 L/min/m2 with support),

and the trial is now called DanGer Shock. A total of 360 patients are

low-cardiac power output (CPO <0.6 W) and elevated filling pressures

planned to be enrolled to assess the primary outcome of death from

(left ventricular end-diastolic pressure > 18 mmHg or right atrial

all causes at 6 months. Inclusion criteria of study participants include:

pressure > 10–15 mmHg) along with cool extremities, lactic acidosis,

STEMI for <36 hr, CS for <24 hr, confirmed based on arterial blood

and/or evidence of end-organ dysfunction. Despite the CS criteria

lactate ≥2.5 mmoL/L and/or SvO2 < 55% with a normal PaO2 and

outlined above, CS tends to present on a wide continuum and patient

systolic BP < 100 mmHg and/or need to vasopressor therapy, and a

phenotypes are highly variable with presentations driven by underly-

left ventricular ejection fraction <45%. Since the study initiation in

ing cardiac etiology, presence or absence of prior cardiac dysfunction

December 2012, about 150 patients have been enrolled through the

and duration of CS.38 While prolonged shock is associated with worse

8

BASIR ET AL.

outcomes, the onset of CS is often hard to pinpoint. Timing for enroll-

survival benefit from RCTs. MCS are costly and range from

ment into RCT is therefore critical in evaluating the efficacy of MCS in

$10,000–30,000 with Medicare Severity Diagnosis Related Groups

a particular stage of CS. As mentioned previously investigators in the

(MS-DRG) reimbursement reaching $100,000.

IMPRESS trial originally intended to recruit patients in pre-shock
(SCAI Shock Stage B); however, substantial difficulties were encountered that required changes to their inclusion criteria ultimately lead-

5
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ing to recruitment of patients in deteriorating shock (SCAI Shock
Stage D), exemplifying the difficulties in recruiting across the shock

Taking into account the aforementioned challenges in conducting

continuum. Thus, while a minimum level of hemodynamic compromise

RCTs using MCS in AMICS, investigators are left with the challenge of

is necessary for an inclusion definition, trials must be similarly cogni-

designing trials that will accomplish the objectives of determining effi-

zant of the worst level of shock acceptable in a given trial, so as not to

cacy while balancing issues such as low recruitment, cross over, and

include patients who have little to gain from a given therapy (i.e., the

cost. Suggested efficacy end points are listed in Table 3.

futile patient).

The DAWN trial in ischemic stroke provides a template for an
innovative trial design that lends itself well to some of these challenges.38 Briefly, the DAWN trial randomly assigned patients with an

4.3
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FDA approval

ischemic stroke to receive late endovascular thrombectomy or standard therapy. After 206 patients were enrolled, the trial was stopped

Ethical concerns are an additional impediment to enrollment. In con-

for efficacy; Bayesian posterior probabilities of >0.999 suggested

trast to FDA requirements for new drugs, medical devices are subject

strong evidence in favor of thrombectomy. The DAWN trial has two

to a separate approval pathway. When a device already has an indica-

interesting design features that lend themselves nicely to a trial of

tion for use, physicians charged with the care of these patients may

MCS in AMICS .

perceive it to be unethical to randomize patients not to receive MCS.

First, this design allows frequent interim analyses for benefit

Hence, with market expansion, physicians are left under a cloud of

and harm without compromising the validity of the final results.

uncertainty regarding the ethics of withholding treatment in a ran-

With a trial design based on Bayesian posterior probabilities of suc-

domized trial. In an ideal world regulatory and clinical treatment deci-

cess, the investigators planned to conduct interim analyses after

sions should be based on assessment of treatment effectiveness and

enrollment of 150 patients and again after every 50 patients there-

safety based on RCT data. Approvals that are based solely on data

after up to a maximum enrollment of 500 patients; thanks to the

that do not involve a well-structured RCT can result in patients and

adaptability of this design, the trial was stopped after enrolling

clinicians practicing with uncertainties regarding the benefits and

206 patients with strong and uniform signs of efficacy (Bayesian

harms associated with new medical devices and therapies.

posterior probability >0.999 for superiority). Had there been a
smaller benefit that was not conclusive at the interim analysis, the
trial would have continued until sufficient data accrued to conclude

4.4

|

Crossover

that (1) there was a true benefit or (2) there was no benefit. While
the specific number of patients required and interim strategy

In order to most efficiently test a hypothesis that an intervention

deployed for a MCS trial would be dependent on other operating

works, a RCT should minimize bail-out crossover from the medical

characteristics, the key takeaway is that this design allows us to

therapy arm to MCS. Cardiologists, however, may feel that not having

enroll “just as many” patients as needed to answer the question,

a bail-out option would be unethical leaving a critically ill patient to

thereby minimizing patient exposure. This provides a practical

die. Even without a RCT proving mortality benefit, MCS devices are

advantage as well as since it is difficult to enroll these patients into

implanted in an effort to improve hemodynamics with the belief that

trials. It also may mitigate ethical concerns by exposing the fewest

their efforts will result in improved survival. Early adopters of MCS

patients needed to obtain a valid answer.

who have a perception of improving outcomes therefore may be less

Second, the adaptive-enrichment strategy allows for fine tuning

likely to participate in such trials. As utilization continues, particularly

of the patient population at interim analyses. The DAWN trial for

in the United States, the perception has left many to wonder if such

example prespecified five patient subpopulations based on infarct

trials can only take place outside of the United States. Trials, which

size. At each planned interim analysis, if the highest currently open

will allow cross over will also need to have strict definitions and

group had less than 40% probability of demonstrating an average pos-

parameters when such cross over can or should occur.

itive treatment effect, enrollment of patients in that group would be
suspended. Thereby concluding that the experimental treatment was
“futile” in that population and that there was nothing to be gained by

4.5

|

High reimbursement

continuing to enroll those patients. The study would remain open in
the other groups. A similar design could be quite useful in AMICS if

Given the current crisis of healthcare costs, one may also question

prespecified subgroups were identified to eliminate patient groups

why the system is paying for expensive MCS in the absence of

where MCS was demonstrating little evidence of benefit. Subgroups

9
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for example could be based upon SCAI shock stages or a variation of

on whether to stop the trial. For the first group of 30 patients,

the stages.39

patients were randomized in a 1:1 allocation ratio; if the trial contin-

If MCS has a strong and uniform survival benefit, the trial would

ued, randomization to the subsequent group of participants was to

terminate relatively early and have conclusive proof of efficacy with a

be weighted in proportion to the posterior probability of the superior

relatively small number of patients exposed. If MCS has a strong sur-

treatment at the most recent analysis. Like DAWN, the study was

vival benefit in some patients but not all, the trial could be designed

terminated at the first interim analysis (30 patients) because the pos-

to suspend enrollment as soon as efficacy was proven for the sub-

terior probability of superiority exceeded the prespecified monitoring

group in which benefit has been proven while enrollment in the other

boundary; six patients that had been randomly assigned to early

subgroups remains open long enough to determine whether benefit

ECMO had survived versus just one in the standard ACLS group for a

extends to those groups. If MCS has little or no survival benefit in any

posterior probability of benefit of 0.986 with ECMO versus ACLS.

patients, the trial will enroll just long enough to rule out benefit in all

These trial designs are potentially attractive in the setting of CS

patients. If MCS has a strong harmful tendency in some patients,

research, a high-mortality population where treatments may have

enrollment will likely be suspended in the specific subgroups in which

very large treatment effects. By performing frequent interim analyses

harm has been proven very quickly while remaining open long enough

that allow for stopping once the data are sufficiently convincing to

to rule out benefit in the other subgroups. If MCS has a strong and

meet a prespecified threshold for success, the trial can be “rightly-

uniform harmful tendency, the trial would again terminate relatively

sized” to enroll just as many participants as needed to establish ther-

early with conclusive evidence against the use of MCS.

apeutic efficacy without going further and randomizing participants

Another potential model is the recently published ARREST trial

beyond the point where the data are sufficient to prove that the ther-

of reperfusion strategies in patients with out-of-hospital cardiac

apy is effective. Such trials may also specify a maximum sample size;

arrest and refractory ventricular fibrillation. Patients were randomly

if a stopping rule is not met at any of the previously conducted

assigned to ECMO-facilitated resuscitation versus initial standard

interim analysis, the trial will cease and provide a final estimate of

advanced cardiac life support (ACLS) treatment. Like the DAWN trial,

treatment based on the observed data.

ARREST was designed using Bayesian group sequential monitoring in

Planning this trial would require outlining the important trial oper-

efforts to maximize efficiency, with planned response adaptive ran-

ating characteristics including: estimated mortality in control arm, pos-

domization if the trial continued past the first interim analysis. The

sible effect sizes, definition of subgroups, agreed-upon Bayesian

design planned for interim analyses after every 30 participants

probability thresholds for futility, and so on. Similarly, we would need

followed-up for the primary endpoint, potentially enrolling up to

to conduct extensive simulations to ensure that the design would

150 total participants. If strong evidence was found of an effect on

function well under variations of these parameters. The NCSI network

survival to hospital discharge (posterior probability of 0.986 or

along with other collaborative networks could come together to per-

higher) the DSMB was obliged to provide a formal recommendation

form such a study.

TABLE 3

Suggested end points in a RCT for AMICS

Primary end point
Short-term (30–90 day) survival
Secondary end points
Need for MCS upgrade
MCS major complications (BARC 5 bleeding, amputation, CVA CPC 3–5)
6-month and 1-year survival
6-month and 1-year heart failure admissions
Other end points
Hemodynamic effects (RA, PA, HR, BP, CO, CI)
Utilization of inotropes and vasopressors
End-organ perfusion (GFR, Cr, AST, ALT, lactate)
Shock stage (A, B, C, D, E)
MCS complications (BARC 2–4 bleeding, surgical interventions, peripheral interventions)
Adverse events (CVA 1–2, transfusion, limb ischemia, MI, new ventilator/dialysis requirement at discharge)
Need for durable MCS or transplant
Discharge disposition (home, rehab, long-term acute care facility)
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; BARC, Bleeding Academic Research Consortium; BP, blood pressure; CI, cardiac
index; CO, cardiac output; Cr, creatinine; CVA, cerebral vascular attack; GFR, glomerular filtration rate; HR, heart rate; MCS, mechanical circulatory
support, MI, myocardial infarction; PA, pulmonary artery pressure; RA, right atrial pressure.
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The NCSI enrolled patients with similar inclusion and exclusion
criteria when compared to the Shock and IABP-Shock Trials. If we
assume 41% mortality in the control arm, similar to the outcomes seen
the IABP-Shock trial and a 28% mortality in the intervention arm, similar to the outcomes seen in the NCSI, a traditional trial design planning
to enroll 500 patients would have approximately 87% power.
An adaptive trial design in the model of DAWN or ARREST would
have potential to conduct this trial even more efficiently. As an example: suppose that the trial is designed to enroll up to a maximum of
500 patients (using 1:1 randomization throughout), with planned
interim analysis after each group of 50 patients enrolled, allowing for
efficacy termination if the posterior probability of superiority exceeds
0.99 for one treatment group. Under the same assumptions used
above, in 100,000 simulations we demonstrate that the trial would
have comparable power to the traditional design (about 86%) with an
additional benefit that the majority of such trials would stop before
enrolling 500 participants (mean number of about 296 participants
required) while controlling the Type I error rate at about 5% overall.
The ability for trials to terminate early in the setting of a very large
observed mortality benefit is an attractive feature of the adaptive
design in high-mortality populations.

6

|

C O N CL U S I O N S

AMI complicated by CS is associated with substantial morbidity and
mortality. There has been an increasing utilization of MCS devices for
management of such patients to improve hemodynamics, facilitate
revascularization, and preserve end organ function. MCS devices are
expensive and invasive interventions with inherent industry, physician, and health system financial interests that may increase utilization. Well-powered RCTs are difficult to conduct in a critically ill
patient population due to physician practice preferences, perceived
lack of equipoise, and challenges in obtaining informed consent.
Despite these challenges it is imperative to guide physicians with the
most compelling level of evidence. Given uncertainty stemming from
observational studies suggesting both benefit and harm when utilizing
MCS, physician leaders and regulatory bodies must come together to
ensure trials are conducted to provide the safest, most evidencebased care for our patients.
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